目的:探讨放疗联合热疗治疗晚期卵巢癌术后复发的临床疗效。方法:选择哈医科大学第四临床医院及黑龙江省第二肿瘤医院2010年3月~2013年3月收治的68例卵巢癌术后复发患者(均为术后化疗6-8个疗程盆腔复发),将其随机分为热疗联合放疗组(实验组)和单纯化疗组(对照组)。所有患者均给予化疗6-8个周期以上,实验组在放疗结束后2小时内进行热疗,2次/周,共6-8周。通过影像学检查治疗前后肿瘤体积的变化进行疗效评估,观察两组治疗期间各种不良反应的发生情况及术后3年的生存情况。结果:观察组肿瘤完全缓解率(CR)实验组明显高于对照组(P<0.05)。皮肤损伤的发生率显著高于对照组,而白细胞计数下降的发生率明显低于对照组(P<0.05)。两组随访1、2年的生存率无明显差异(P>0.05),实验组第3年的生存率明显高于对照组(P<0.05)。结论:热疗联合放疗可提高晚期卵巢癌术后复发的临床疗效。 Objective: To investigate the clinical efficacy of radiotherapy combined with hyperthermia in the treatment of postoperative recurrence of advanced ovarian cancer. Methods: Sixty-eight patients with postoperative recurrence of ovarian cancer who were admitted to the Fourth Clinical Hospital of Harbin Medical University and the Second Tumor Hospital of Heilongjiang Province from March 2010 to March 2013 were recruited for pelvic recurrence after 6-8 cycles of chemotherapy. , Which were randomly divided into hyperthermia combined with radiotherapy (experimental group) and chemotherapy alone group (control group). All patients were given chemotherapy more than 6-8 cycles, the experimental group within 2 hours after the end of radiotherapy hyperthermia, 2 times / week, a total of 6-8 weeks. The changes of tumor volume before and after imaging examination were used to evaluate the curative effect. The incidence of various adverse reactions and survival after 3 years of operation were observed in both groups. Results: The complete remission rate (CR) in observation group was significantly higher than that in control group (P <0.05). The incidence of skin lesions was significantly higher than the control group, while the incidence of white blood cell count decreased significantly lower than the control group (P <0.05). There was no significant difference in the survival rates between the two groups at 1 and 2 years (P> 0.05). The 3-year survival rate of the experimental group was significantly higher than that of the control group (P <0.05). Conclusion: Hyperthermia combined with radiotherapy can improve the clinical efficacy of postoperative recurrence of advanced ovarian cancer.